A PCA test most commonly refers to a Parietal Cell Antibody test, a blood test used to help diagnose pernicious anemia and autoimmune gastritis. The term “PCA test” can also refer to the PCA3 test, a urine-based test used in prostate cancer evaluation. These are entirely different tests for different conditions, so understanding which one your doctor ordered (or which one you’re reading about) matters.
The Parietal Cell Antibody Blood Test
Parietal cells line your stomach and do two critical jobs: they produce the acid that breaks down food, and they make a protein called intrinsic factor that your body needs to absorb vitamin B12. In autoimmune gastritis, your immune system mistakenly attacks these cells by producing antibodies against them. The PCA test detects those antibodies in your blood.
A positive result means your immune system is targeting a specific enzyme on the surface of your parietal cells, the pump responsible for producing stomach acid. Over time, this attack destroys parietal cells, which reduces both acid production and intrinsic factor. Without intrinsic factor, your body can’t absorb B12 from food, eventually leading to pernicious anemia.
Doctors typically order this test when you show signs of B12 deficiency: fatigue, numbness or tingling in your hands and feet, difficulty concentrating, or a specific type of anemia where red blood cells are abnormally large. No fasting or special preparation is needed. It’s a simple blood draw.
How Accurate Is the Parietal Cell Antibody Test?
The PCA test has a sensitivity of about 68% and a specificity of about 92% for diagnosing pernicious anemia. In practical terms, this means it catches roughly two out of three cases, but when it does come back positive, it’s highly reliable. About 65% of people with confirmed autoimmune gastritis test positive for parietal cell antibodies, compared to only about 14% of healthy controls.
Because the test misses some cases on its own, doctors often pair it with an intrinsic factor antibody (IFA) test. The IFA test is more specific (nearly 99%) but less sensitive, catching only about 41% of pernicious anemia cases. When both tests are used together, the combined sensitivity jumps to about 86% with a specificity around 90%. The two tests complement each other: the PCA test casts a wider net, while the IFA test provides stronger confirmation.
One important distinction is timing. Parietal cell antibodies tend to appear earlier in the disease process, sometimes years before full-blown pernicious anemia develops. Intrinsic factor antibodies show up at later stages. This makes the PCA test useful not just for diagnosis but as a predictive marker for people at risk of developing stomach lining damage and B12 deficiency down the road.
Who Should Get Tested
Parietal cell antibodies are more common in people who already have another autoimmune condition. They show up at higher rates in people with type 1 diabetes, autoimmune thyroid diseases like Hashimoto’s, vitiligo, and celiac disease. If you have one of these conditions and develop unexplained anemia or neurological symptoms like tingling or balance problems, the PCA test can help determine whether autoimmune gastritis is the cause.
The test is also relevant if you have chronic, unexplained B12 deficiency that doesn’t respond well to oral supplements, since the underlying problem may be an inability to absorb B12 in the gut rather than a dietary shortfall.
The PCA3 Prostate Cancer Urine Test
The PCA3 test is an entirely different test used in prostate cancer screening. It measures genetic material (called PCA3 mRNA) that prostate cancer cells produce in much higher amounts than normal prostate cells. Unlike the standard PSA blood test, which can be elevated for many non-cancerous reasons like an enlarged prostate or infection, PCA3 is more specific to cancer.
This test is primarily used for men who have already had an elevated PSA level but whose initial prostate biopsy came back negative. In that situation, the question is whether a repeat biopsy is worthwhile. The PCA3 test helps answer that question.
How the PCA3 Test Works
Collection requires a digital rectal exam (DRE) immediately before giving a urine sample. During the DRE, the doctor applies pressure to each side of the prostate, which releases prostate cells into the urinary tract. You then provide a urine sample, and the lab measures the ratio of PCA3 genetic material to PSA genetic material. Research has shown that PCA3 can sometimes be detected in urine even without a DRE, but the exam significantly improves the test’s reliability.
Understanding PCA3 Scores
The result comes back as a numerical score. The FDA-approved cutoff is 25. A score below 25 is considered negative and suggests a lower likelihood that a repeat biopsy would find cancer. A score of 25 or higher is considered positive, indicating a higher probability that cancer is present and that a repeat biopsy may be warranted. The score doesn’t diagnose cancer on its own. It’s a decision-making tool that helps you and your doctor weigh whether the risks and discomfort of another biopsy are justified.
PCA vs. PCA3: Key Differences
- What it detects: The PCA test looks for immune antibodies attacking stomach cells. The PCA3 test measures genetic material shed by prostate cells.
- Sample type: PCA is a standard blood draw. PCA3 requires a urine sample collected after a digital rectal exam.
- Who it’s for: PCA is ordered for people with suspected B12 deficiency or autoimmune gastritis, regardless of sex. PCA3 is used exclusively in men with a prior elevated PSA and a negative biopsy.
- Preparation: The PCA blood test requires no preparation. The PCA3 urine test requires the DRE to be performed immediately beforehand.
If you’re unsure which test your doctor has recommended, the simplest way to tell is the sample: if it’s a blood test, it’s the parietal cell antibody test. If it involves a urine sample after a prostate exam, it’s the PCA3 test.